Literature DB >> 35127687

Editorial: The Molecular Mechanisms of Synaptic Plasticity Impairments in Alzheimer's Disease.

Gong-Ping Liu1,2, Peng Lei3, Zhi-Fang Dong4, Shu-Peng Li5.   

Abstract

Entities:  

Keywords:  Alzheimer’s disease; cognition; dendritic plasticity; spine; synaptic plasticity

Year:  2022        PMID: 35127687      PMCID: PMC8814519          DOI: 10.3389/fcell.2022.832728

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


× No keyword cloud information.
Synaptic plasticity, which is directly related to memory and learning processes, is determined by morphological and functional modifications of synapses. Long-term potentiation and long-term depression are two main manifested forms of synaptic plasticity. Dendritic spines are small, highly dynamic protruding structures in the dendritic membrane, which have specialized subdomains with specific functions in synaptic transmission and plasticity, including scaffolding proteins, ion channels, cytoskeleton components, signal transduction molecules, and postsynaptic density (a complex mainly consisted by AMPAR and NMDAR) (Saneyoshi et al., 2010; González-Burgos, 2012). Structural changes, such as spines elongation and contraction, shape variations, spine distribution/density and functions mediate synaptic plasticity (Chidambaram et al., 2019). Impairments of synaptic plasticity, such as spine shape and density alteration, lead to synaptic dysfunction and cognitive impairment, which is found in many neurodegenerative diseases, including Alzheimer’s disease (AD). Aberrant synaptic structure/morphology and decreased spine density in the hippocampus and neocortex is an early event and a major change, correlated with cognitive deficits in AD (Scheff et al., 1990; Scheff and Price, 2003), which usually appear well before neuronal loss. However, questions about the details and mechanisms of synaptic plasticity dysfunction in AD still warrant further studies, as in contrast with the well documented synaptic dysfunction elicited by pathological factors of accumulated phosphorylated tau and amyloid β peptide (Aβ). This topic focused on “The Molecular Mechanisms of Synaptic Plasticity Impairments in Alzheimer’s Disease,” and there were 21 manuscripts to be expected, 13 manuscripts actually submitted and 10 manuscripts accepted. In this issue of frontiers, Mahaman et al. reviewed the role of STriatal-Enriched protein tyrosine phosphatase (STEP) in dendritic plasticity impairments in AD, whose level and activity are increased in AD via Aβ. STEP dephosphorylated and inactivated synaptic proteins via kinases such as Fyn, Pyk2 and ERK1/2 (Venkitaramani et al., 2009; Li et al., 2014), and it also led to the internalization of synaptic receptor complexes like GluN2B/GluN1 and GluA2/GluA1 subunits of NMDA and AMPA receptors, respectively (Poddar et al., 2010; Zhang et al., 2010). Furthermore, STEP dephosphorylated SPIN90 to dissociate from cofilin, and activated cofilin to depolymerize F-actin to G-actin. Together, increase of STEP led to synapse loss and dendritic plasticity impairments, and ultimately, resulting in cognitive deficits in AD. Transmembrane protein 59 (TMEM59) reported to associate with AD was introduced by Meng et al. They showed that TMEM59 haploinsufficiency rescued memory defects and synaptic plasticity dysfunction in 5×FAD mice, which overexpressing human APP and PSEN1 transgenes with a total of five AD-linked mutations: the Swedish (K670N/M671L), Florida (I716V), and London (V717I) mutations in APP, as well as M146L and L286V mutations in PSEN1, and rapidly developing severe amyloid pathology and presenting synaptic degeneration. The authors found that overexpression of TMEM59 in the hippocampus caused memory deficits and had a trend to induce synaptic plasticity impairment in wild-type mice, which suggesting its neurotoxic role. Interestingly, while TMEM59 overexpression had no effect on worsening synaptic defects and impaired memory in the 5×FAD mouse model of AD, though it significantly exacerbated AD-like pathologies by increasing levels of detergent-insoluble Aβ and Aβ plaques. They proposed that, due to a mild impact on cognitive and synaptic function impairments, overexpressing TMEM59 may not be able to further worsen the quickly degenerative phenotypes in 5×FAD mice. As one of the main pathophysiologic markers in AD, hyperphosphorylated tau led to the dissociation of Tau/Fyn/PSD-95/NMDAR complex, the disruption of synaptic potentiation required for LTP (Frandemiche et al., 2014), and the reduction of functional dendritic spine number (Tracy and Gan, 2018). Overexpressing tau decreased NMDAR level by activation of STAT1 and inactivation of STAT3 (Li et al., 2019; Hong et al., 2020). Jiang et al. found that, PINK1 overexpression ameliorated the decreased dendritic spine density via autophagy activation to decrease total and phosphorylated tau. In addition to abnormal aggregated tau or Aβ, multiple other risk factors, such as aging, oxidative stress, calcium signal dysregulation, neuroinflammation, genetic and environmental factors, could induce synaptic plasticity defects. In this issue of frontier, a study demonstrated that maternal lead (Pb) exposure induced synaptic plasticity impairment of offspring by reducing GLUT4 protein level in the cell membrane as well as glucose uptake via the PI3K-Akt signaling pathway. Mitochondrial dysfunction is a well-established early etiological event in AD, which decreases ATP production, changes cytoplasmic calcium concentrations, and increases ROS/NO production, consequently leading to synaptic plasticity abnormalities. Huang et al. and Chen et al., respectively, found that, tetramethylpyrazine or dauricine, the extract from the rootstock of traditional Chinese medicine, modified the mitochondrial protein profile of AD animal models to increase ATP production and some synapse-related protein expression, and ultimately, improved synaptic plasticity and cognition. Most of the accepted articles in this research topic contributed to expand and deepen our understanding of the risk factors and its mechanisms for synaptic plasticity damage in AD, and we understand that gestational Pb exposure could induce synaptic plasticity impairment of offspring, and etramethylpyrazine and dauricine ameliorate synaptic plasticity, which both are not reported previously. However, some questions, which we have a lot of interest in, are missing in this topic. For example, is LTP impairment caused by directly reduced synapse numbers or decreased synaptic transmission efficiency? What are the inherent molecular mechanisms underlying the aberrant spine number loss (synaptic-associated protein loss, microglia-mediated synapse elimination, neuroinflammation, neuron apoptosis or death)? We hope that the articles in this topic will be of interest to a broad range of researchers working in dendritic plasticity in AD, stimulating experimental work relating to the mechanisms of synaptic plasticity impairments and therapeutic strategies. In a future topic collection, we would like to see more articles about new molecular strategies directly targeting to promote synaptic plasticity.
  13 in total

1.  Molecular mechanism of ERK dephosphorylation by striatal-enriched protein tyrosine phosphatase.

Authors:  Rong Li; Di-Dong Xie; Jun-Hong Dong; Hui Li; Kang-Shuai Li; Jing Su; Lai-Zhong Chen; Yun-Fei Xu; Hong-Mei Wang; Zheng Gong; Guo-Ying Cui; Xiao Yu; Kai Wang; Wei Yao; Tao Xin; Min-Yong Li; Kun-Hong Xiao; Xiao-Fei An; Yuqing Huo; Zhi-Gang Xu; Jin-Peng Sun; Qi Pang
Journal:  J Neurochem       Date:  2013-10-31       Impact factor: 5.372

2.  Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers.

Authors:  Marie Lise Frandemiche; Sandrine De Seranno; Travis Rush; Eve Borel; Auréliane Elie; Isabelle Arnal; Fabien Lanté; Alain Buisson
Journal:  J Neurosci       Date:  2014-04-23       Impact factor: 6.167

Review 3.  Dendritic spines: Revisiting the physiological role.

Authors:  Saravana Babu Chidambaram; A G Rathipriya; Srinivasa Rao Bolla; Abid Bhat; Bipul Ray; Arehally Marappa Mahalakshmi; Thamilarasan Manivasagam; Arokiasamy Justin Thenmozhi; Musthafa Mohamed Essa; Gilles J Guillemin; Ramesh Chandra; Meena Kishore Sakharkar
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-01-15       Impact factor: 5.067

4.  Tau accumulation triggers STAT1-dependent memory deficits by suppressing NMDA receptor expression.

Authors:  Xiao-Guang Li; Xiao-Yue Hong; Ya-Li Wang; Shu-Juan Zhang; Jun-Fei Zhang; Xia-Chun Li; Yan-Chao Liu; Dong-Shen Sun; Qiong Feng; Jin-Wang Ye; Yuan Gao; Dan Ke; Qun Wang; Hong-Lian Li; Keqiang Ye; Gong-Ping Liu; Jian-Zhi Wang
Journal:  EMBO Rep       Date:  2019-05-13       Impact factor: 8.807

5.  From synaptic transmission to cognition: an intermediary role for dendritic spines.

Authors:  Ignacio González-Burgos
Journal:  Brain Cogn       Date:  2012-04-17       Impact factor: 2.310

Review 6.  Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease.

Authors:  Tara E Tracy; Li Gan
Journal:  Curr Opin Neurobiol       Date:  2018-05-10       Impact factor: 6.627

Review 7.  Regulation of spine and synapse formation by activity-dependent intracellular signaling pathways.

Authors:  Takeo Saneyoshi; Dale A Fortin; Thomas R Soderling
Journal:  Curr Opin Neurobiol       Date:  2009-11-04       Impact factor: 6.627

8.  Quantitative assessment of cortical synaptic density in Alzheimer's disease.

Authors:  S W Scheff; S T DeKosky; D A Price
Journal:  Neurobiol Aging       Date:  1990 Jan-Feb       Impact factor: 4.673

Review 9.  Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies.

Authors:  Stephen W Scheff; Douglas A Price
Journal:  Neurobiol Aging       Date:  2003-12       Impact factor: 4.673

10.  STAT3 ameliorates cognitive deficits by positively regulating the expression of NMDARs in a mouse model of FTDP-17.

Authors:  Xiao-Yue Hong; Hua-Li Wan; Ting Li; Bing-Ge Zhang; Xiao-Guang Li; Xin Wang; Xiao Li; Qian Liu; Chong-Yang Chen; Ying Yang; Qun Wang; Shu-Peng Li; Hao Yu; Jian-Zhi Wang; Xi-Fei Yang; Gong-Ping Liu
Journal:  Signal Transduct Target Ther       Date:  2020-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.